Success Metrics

Clinical Success Rate

61.5%

Based on 8 completed trials

Completion Rate

62%(8/13)

Active Trials

3(13%)

Results Posted

63%(5 trials)

Terminated

5(21%)

Phase Distribution

Ph phase_2

38%

Ph early_phase_1

13%

Ph phase_1

Ph phase_3

17%

Ph not_applicable

29%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution24 total trials

Early Phase 1First-in-human

3(12.5%)

Phase 1Safety & dosage

1(4.2%)

Phase 2Efficacy & side effects

9(37.5%)

Phase 3Large-scale testing

4(16.7%)

N/ANon-phased studies

7(29.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

8 of 16 finished

Non-Completion Rate

50.0%

8 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Completed(8)

Terminated(8)

Other(4)

Detailed Status

Completed8

Terminated5

unknown4

Withdrawn3

Recruiting2

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

61.5%

Most Advanced

Phase 3

Trials by Phase

Early Phase 13 (12.5%)

Phase 11 (4.2%)

Phase 29 (37.5%)

Phase 34 (16.7%)

N/A7 (29.2%)

Trials by Status

active_not_recruiting14%

completed833%

recruiting28%

withdrawn313%

unknown417%

not_yet_recruiting14%

terminated521%

Recent Activity

3 active trials

Showing 5 of 24

active_not_recruitingearly_phase_1

Glutathione in Mild Cognitive Impairment

NCT03493178

not_yet_recruitingnot_applicable

Dietary Glycine Supplementation in Metabolic Dysfunction-associated Steatotic Liver Disease

NCT07285135

recruitingnot_applicable

Clinical Trials (24)

Showing 20 of 24 trialsScroll for more

NCT03493178Early Phase 1

Glutathione in Mild Cognitive Impairment

Active Not Recruiting

NCT07285135Not Applicable

Dietary Glycine Supplementation in Metabolic Dysfunction-associated Steatotic Liver Disease

Not Yet Recruiting

NCT06959251Not Applicable

Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia

Recruiting

NCT04740580Early Phase 1

Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease

Recruiting

NCT04703036Early Phase 1

Glutathione, Oxidative Stress and Mitochondrial Function in COVID-19

Terminated

NCT04443673Not Applicable

Glycine Supplement for Severe COVID-19

Terminated

NCT04658134Not Applicable

Glycine "Deficiency" and the Kinetics of Acylglycine in Morbid Obesity

Unknown

NCT00291226Phase 2

Glycine vs Placebo for the Schizophrenia Prodrome

Completed

NCT00222235Phase 2

Adjunctive Treatment for Decreasing Symptoms of Schizophrenia

Completed

NCT03850314Phase 2

The Effects of Glycine on Atherosclerosis and Metabolic Syndrome-related Parameters.

Unknown

NCT00338598Phase 2

Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism

Completed

NCT01720316Phase 2

Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders

Completed

NCT03180775Not Applicable

Effects of Dietary Amino Acids on Serum and Macrophage Atherogenicity

Unknown

NCT00405535Not Applicable

Adjunctive Glycine for Obsessive Compulsive Disorder

Completed

NCT02315391Not Applicable

Protein Nutrition for Muscle Hypertrophy in Older Adults

Completed

NCT01417481Phase 2

Effect of Glycine in Cystic Fibrosis

Terminated

NCT00000372Phase 3

Glycine and D-Cycloserine in Schizophrenia

Withdrawn

NCT00913692Phase 2

A Randomized Double-Blind Control-Comparison Crossover Trial of Oral Glutamine to Suppress Frequently Recurrent Herpes Labialis

Terminated

NCT00268749Phase 2

Glycine Treatment of Prodromal Symptoms

Completed

NCT00133406Phase 3

Long-term Impact and Intervention for Diarrhea in Brazil

Unknown

Drug Details

Intervention Type: DIETARY SUPPLEMENT
Total Trials: 24